We demonstrated that tumours that lose ERα‐expression during disease progression, retained a proteomic signature more similar to ERα‐P metastases (derived from ERα‐P primary disease), as opposed to ERα‐N metastases (derived from ERα‐N primary disease). This evidence concerns the gene ESR1 and neoplasm.